Topical immunotherapy: unapproved uses, dosages, or indications.
Higgins
Elisabeth
E
Department of Dermatology, King's College Hospital, London, England. elisabeth.higgins@kcl.ac.uk
du Vivier
Anthony
A
D000287:Administration, Topical; D000328:Adult; D000506:Alopecia Areata / Q000175:diagnosis / Q000188:drug therapy*; D002648:Child; D018849:Controlled Clinical Trials as Topic; D003521:Cyclopropanes / Q000008:administration & dosage* / Q000009:adverse effects; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D017277:Drug Approval; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D018570:Risk Assessment; D016896:Treatment Outcome; D006113:United Kingdom; D014860:Warts / Q000175:diagnosis / Q000188:drug therapy*
D003521:Cyclopropanes; D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; C029402:diphenylcyclopropenone